Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
ConditionColo-rectal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age45-75
SponsorEpiliquid Holding, Inc
About this trial
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, for the detection of colorectal cancer. Epiliquid also integrates a proprietary bioinformatic system capable of identifying, ranking, and selecting tumor-specific methylation biomarkers for different cancer types. In this study, colorectal cancer-specific biomarkers will be evaluated in blood and tissue samples using delta-HLD technology, which enables sensitive and multiplexed detection through PCR. Study results will support the validation of Epiliquid's integrated platform as a minimally invasive and accessible diagnostic solution for colorectal cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Candidate for colonoscopy or colorectal surgery
Willing and able to provide informed consent
Able to provide blood and/or tissue sample before treatment or resection
Disqualifiers
Prior history of colorectal cancer
Inflammatory bowel disease
Known hereditary cancer syndromes (e.g., Lynch, FAP)
Other active malignancies
Trial population
Adults aged 45 to 75 years from an average-risk population for colorectal cancer, undergoing colonoscopy or colorectal surgery at participating clinical sites in Argentina.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
600 Participants
are grouped into 2 trial groupsGroup A: CRC Cases
Group B: Controls
Trial outcomes
Primary outcomes
1
Sensitivity and Specificity of delta-HLD Technology for Colorectal Cancer
Diagnostic performance of methylation biomarkers detected using delta-HLD technology in plasma and tissue samples, using colonoscopy and histopathology as the clinical reference standard.
Time frame
Within 3 months after sample collectionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov